Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
h1n1 influenza vaccine
- Development stage
- Unknown
- Lead developer
- CSL
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
The H1N1 influenza vaccine is a monovalent or trivalent inactivated or recombinant vaccine designed to protect against the Influenza A (H1N1) virus, which is also known as "swine flu." It works by stimulating the immune system to produce antibodies against the H1N1 viral antigens, thereby providing immunity and reducing the risk of infection. The specific strains included in the vaccine are updated annually based on global surveillance data. For example, for the 2025-2026 U.S. season, egg-based vaccines include an A/Victoria/4897/2022 (H1N1)pdm09-like virus. The primary indication is prevention of influenza caused by H1N1 viruses.
- Brand names
- AFLURIA
- Other names
- swine flu vaccineInfluenza A (H1N1) 2009 Monovalent Vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on h1n1 influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on h1n1 influenza vaccine.